Work

LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Year: 2023

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.10.029

Authors: I.B. Vergote, A. Gonzalez Martin, K. Fujiwara, E. Kalbacher, A. Bagameri, S. Ghamande, J-Y. Lee, S. Banerjee, F.C. Maluf, D. Lorusso, K. Yonemori, E. Van Nieuwenhuysen, L.M. Manso Sanchez, L. Woelber, A.M. Westermann, A. Covens, E. Whalley, M.S.L. Teng, I. Soumaoro, B.M. Slomovitz

Institutions: Universitair Ziekenhuis Leuven, KU Leuven, Clinica Universidad de Navarra, Spanish Ovarian Cancer Research Group, Saitama International Medical Center, Saitama Medical University, Centre Hospitalier Universitaire de Besançon, Augusta University, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Beneficência Portuguesa de São Paulo, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, National Cancer Centre Japan, Hospital Universitario 12 De Octubre, University Medical Center Hamburg-Eppendorf, Amsterdam University Medical Centers, Sunnybrook Health Science Centre, Sunnybrook Hospital, Sunnybrook Research Institute, Seagen (United States), Genmab (United States), Mount Sinai Medical Center

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Boston Scientific Corporation, Seagen, University College London, Eisai, Astellas Pharma, Ipsen

OpenAlex ID: W4387809673

FWCI: 9.145

Cites:

Cited by: 34

Related to: 10